Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
TG Therapeutics: The "Exit Velocity" You Can't Ignore (Rating Upgrade)
10:24am, Thursday, 15'th Jan 2026
TG Therapeutics (TGTX) is upgraded from Hold to Strong Buy as BRIUMVI demonstrates accelerating revenue growth and market share gains in the MS market. TGTX guides for 2026 BRIUMVI U.S. net revenue of
Markets News, Jan. 14, 2026: Stock Indexes End Lower After Flurry of Bank Earnings, Economic Data; Gold, Silver Set Fresh Record Highs
07:30pm, Wednesday, 14'th Jan 2026
Major stock indexes ended lower Wednesday as investors digested the latest batch of bank earnings reports and economic data, while safe-haven gold and silver surged to fresh record highs.
TG Therapeutics Soars on Strong Revenue Guidance and BRIUMVI Momentum
12:14pm, Wednesday, 14'th Jan 2026
TG Therapeutics (TGTX) surged today following its revenue guidance for FY25 and FY26. The company anticipates FY25 revenue to reach approximately $616 million,
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
11:55am, Wednesday, 14'th Jan 2026
TGTX jumps after preliminary 2025 sales beat guidance. Its bullish 2026 revenue target and multiple Briumvi pipeline milestones also draw attention.
TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
06:46pm, Tuesday, 13'th Jan 2026
TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TG Therapeutics Stock Climbs After The Bell: Here's Why
05:05pm, Tuesday, 13'th Jan 2026
TG Therapeutics, Inc. (NASDAQ: TGTX) shares climbed in Tuesday's extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 202
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
07:30am, Wednesday, 07'th Jan 2026
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 44th An
TG Therapeutics: What Wall Street Isn't Telling You
11:00am, Tuesday, 30'th Dec 2025
TG Therapeutics, Inc. is my favorite in the multiple sclerosis therapeutics market. In my opinion, it's Briumvi that has the best efficacy among anti-CD20 monoclonal antibodies, including Ocrevus and
Is the Options Market Predicting a Spike in TG Therapeutics Stock?
09:36am, Friday, 19'th Dec 2025
Investors need to pay close attention to TGTX stock based on the movements in the options market lately.
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Analysts
01:27am, Monday, 01'st Dec 2025
TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat.com repor
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
07:30am, Friday, 28'th Nov 2025
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th
TG Therapeutics, Inc. $TGTX Shares Sold by Advantage Alpha Capital Partners LP
03:44am, Friday, 28'th Nov 2025
Advantage Alpha Capital Partners LP lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 30.5% in the second quarter, according to its most recent Form 13F filing with the Securities
Creative Planning Sells 7,534 Shares of TG Therapeutics, Inc. $TGTX
04:42am, Monday, 24'th Nov 2025
Creative Planning lessened its stake in TG Therapeutics, Inc. (NASDAQ: TGTX) by 8.5% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owne
TG Therapeutics: Concerns About Slowing Growth And New Competition
05:23pm, Tuesday, 18'th Nov 2025
TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing
05:49pm, Monday, 17'th Nov 2025
TGTX has seen rapid enrolment of the ENHANCE study which could allow a simplified dosing regime of IV Briumvi. A readout is possible for mid-2026. Investors may need to wait longer for the subcutaneou
